[Hydroxychloroquine and chloroquine for COVID-19: no evidence of effectiveness]. / Hydroxychloroquine en chloroquine bij COVID-19.
Ned Tijdschr Geneeskd
; 1642020 06 02.
Article
en Nl
| MEDLINE
| ID: mdl-32749808
ABSTRACT
On 3 March 2020, the document 'Drug treatment options for patients with COVID-19 (infections with SARS-CoV-2)' was published on the website of the Dutch Working Party on Antibiotic Policy (StichtingWerkgroepAntibioticabeleid, SWAB). Based on a 7-step analysis of the literature, hydroxychloroquine (HCQ) and chloroquine (CQ) were initially included in the SWAB document as possible drug treatments for hospitalised adult COVID-19 patients. However, recent weeks have seen the publication of the results of various studies into the effectiveness of treatment with HCQ and CQ in patients with COVID-19. On the basis of these results, we conclude that there is insufficient evidence to consider HCQ and CQ as meaningful treatment options in patients with COVID-19. Clinically relevant QTc prolongation occurs in at least 1 in 10 COVID-19 patients treated with HCQ or HQ.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neumonía Viral
/
Cloroquina
/
Infecciones por Coronavirus
/
Betacoronavirus
/
Hidroxicloroquina
Límite:
Adult
/
Humans
Idioma:
Nl
Revista:
Ned Tijdschr Geneeskd
Año:
2020
Tipo del documento:
Article